https://www.selleckchem.com/products/ars-1620.html
Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal analysis of mutated cell-free plasma KRAS (cfKRAS ) and CA 19-9 during adjuvant treatment and follow-up might more accurately predict disease course than hitherto available parameters. Between 07/2015 and 10/2018, we collected 134 plasma samples from 25 patients after R0/R1-resection of PDAC during adjuvant chemotherapy and post-trea
Respect!
Kommentar
Delen
